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This report was an overview of pacing therapy for heart failure to explain the usefulness
and problems of CRT in broad terms. It is not an exaggeration to say that pacemakers were
originally developed to improve cardiac function in patients with heart failure. However, it
must be understood that pacing itself is unphysiological, and we should know what pacing
does to the heart. Concerning the simple issue of pacing, it is true that there are a lot of
matters that we think we understand but actually we do not, such as the eﬀects of the
diﬀerences in site, output, and frequency. At least, it seems clear that the currently available
CRT devices are eﬀective for patients with heart failure and for improving survival. Further
improvement in their eﬀectiveness is an important issue we must continue to address.
(J Arrhythmia 2007; 23: 223–228)
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1. Introductions
The history of cardiac pacemakers began in 1932
with Hyman’s invention1) of an external cardiac
stimulator to electrically stimulate the heart from
outside the body using a needle electrode. He named
this stimulator the ‘‘artiﬁcial pacemaker,’’ and this
name is still generally used. In 1958, Furman et al.2)
performed endocardial pacing using an external
pacing device, and Lagergreen et al.3) developed a
prototype of the current VVI (ventricular demand
inhibited) pacemaker in 1963. At ﬁrst, pacemakers
were mainly used to treat bradycardia in clinical
settings, and the primary challenge was to ensure
pacing without any problems, thus technical im-
provement was promoted. More speciﬁcally, there
were many advances and improvements in the lead:
namely, the development of the epicardial and
endocardial leads, improvements in lead material
and tip shape, and development of a screw-in lead
and a steroid-eluting lead.4) Regarding the pace-
maker body, eﬀorts were made to downsize the
body and prolong battery life. After these objectives
were attained, energy was focused on treatment
modalities which were more physiological and
implementation of various diagnostic functions.
The application of pacemakers was extended to
heart failure treatment using bi-ventricular pacing
(cardiac resynchronization therapy, CRT), and now,
CRT-D (cardiac resynchronization therapy with
an implantable cardioverter deﬁbrillator [or ICD]
function), eﬀectively preventing sudden cardiac
death, are now being used in clinical settings. This
report looks back on the history of the use of
pacemakers in patients with heart failure to discuss
their usefulness and the problems associated with
CRT.
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2. Pacemakers for Treatment of Heart Fail-
ure
1) Improvement of heart rate
Originally, pacemakers were developed as a
therapeutic measure to improve the symptoms of
bradycardia, i.e., sudden unconsciousness, vertigo,
and breathlessness. It is well known that breath-
lessness is a symptom associated with heart failure in
many cases and that heart failure due to bradycardia,
even if not associated with atrioventricular block, can
be an indication for pacemaker implantation. Nor-
malization of heart rate was originally seen as being
important in improving cardiac function. That is,
pacemakers constituted a therapeutic measure for
patients with heart failure. The relationship between
heart rate and cardiac output has been discussed for
many years. Even in VVI (ventricular demand)
pacing, cardiac output is increased by increasing the
heart rate from 30 beats/min to 60 beats/min in
patients with normal contractility. When the heart
rate is increased from 80 beats/min to 120 beats/min,
the atrial contraction also has an eﬀect, increasing
cardiac output and showing the growing importance
of atrioventricular synchrony from atrioventricular
sequential excitation.5) In 1987, Benditt et al. reported
that artioventricular synchrony became less impor-
tant for cardiac output and the heart rate was more
deeply involved as it increased.6) In addition, VVI
pacing in patients with bradycardia and atrioventric-
ular conduction was reported to lower cardiac output
to induce pacemaker syndrome.7) These problems
were resolved by atrioventricular sequential pacing,
which was also referred to as physiological pacing.
2) Improvement of atrioventricular synchrony
As described above, normalization of the heart rate
by VVI pacing caused various hemodynamic prob-
lems, and the more aggressive atrioventricular se-
quential pacing using the pacing function, as describ-
ed by Hochleitner in 19908) and Brecker in 1992,9)
became the mainstream treatment for heart failure.
They implanted a DDD (dual chamber) pacemaker in
patients with dilated cardiomyopathy, and observed
improvements in LVEF (left ventricular ejection
fraction), CTR (cardiothoracic ratio), hypotension,
and NYHA (New York Heart Association) class. In
patients with a heart failure condition, such as dilated
cardiomyopathy or atrioventricular sequential exci-
tation, sequential contraction is maintained if sinus
rhythm is maintained. However, this is a hemody-
namic condition in which atrioventricular synchrony
is lost. That is, the atrial contraction phase is
discordant with that of the ventricular contraction,
resulting in a shortened time for blood inﬂow from
the atrium to the left ventricle during ventricular
diastole and mitral regurgitation (MR) during pre-
systole (diastole) occurs. This phenomenon is repro-
duced in ﬁrst-degree atrioventricular block and
observed in heart failure with dilated ventricles when
the PQ interval is within a normal range. Shortening
of the atrioventricular excitation interval by pacing
and improvement of atrioventricular synchrony pro-
long the diastolic left ventricular inﬂow time,
increasing the inﬂow, and decreasing the diastolic
mitral regurgitant ﬂow, all these consequently im-
proving cardiac function. However, the contribution
of DDD pacing to the improvement of heart failure by
correcting ventricular asynchrony has its limits.10)
3) Improvement of ventricular wall motion syn-
chrony
There is no doubt that improved ventricular wall
motion synchrony was a major goal in the aggressive
use of pacemakers to treat heart failure. Meanwhile,
it was gradually clariﬁed that the conventional
method to pace the ventricle from the right ven-
tricular apex had only a limited eﬀect. In 1991, Xiao
et al.11) reported that a widened QRS complex
correlated with a decrease in peak dp/dt and the
time to reach the peak dp/dt, and that cardiac
functions might be improved by narrowing the QRS
complex. In 1996, Cazeau et al.12) reported that
biventricular pacing showed acute and chronic
eﬀects in 8 patients with heart failure. To ascertain
the acute eﬀects, temporary pacing was induced on
the right ventricular apex or right ventricular outﬂow
tract in combination with the left ventricular wall to
examine hemodynamic changes. The results showed
no diﬀerence between the right ventricular outﬂow
tract and right ventricular apex. The cardiac index
was reported to have improved from 1:83 0:30
L/min to 2:25 0:29L/min (p < 0:006), pulmona-
ry arterial wedge pressure from 31 10mmHg to
26 9mmHg (p < 0:01), and v wave amplitude
from 36 12:5mmHg to 26 10mmHg (p < 0:01),
showing an improvement in MR. A pacemaker was
implanted in 6 of the 8 patients (one died from heart
failure before implantation and the other died during
the implantation procedure). A left ventricular lead
was implanted thoracoscopically in 5 of the 6
patients, and biventricular pacing was induced in
the remaining patient. Four of these patients were
followed for 7:7 6:3 months on average. The
symptoms were reported to have improved 2 weeks
after implantation with an improvement in physical
activity from NYHA class IV to class II. The number
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of cases reported by Cazeau et al. was small but theirs
was the ﬁrst report that discussed biventricular pacing
in detail. At ﬁrst, the eﬀectiveness of biventricular
pacing was considered to be closely related to the
improvement in the duration of the QRS complex,
but it was later clariﬁed by echocardiography, RI
cardioangiography, etc., that synchrony in the inter-
ventricular septum and left ventricular free wall as
well as mitral regurgitation was improved by pacing.
3. Usefulness of Biventricular Pacing: Evi-
dence
There have been many prospective multicenter
studies on the eﬀectiveness of biventricular pacing:
namely, PATH-CHF,13) MUSTIC,14) MIRACLE,15)
MIRACLE-ICD,16) CONTAK-CD,17) COMPAN-
ION,18) and CARE-HF.19) The results showed that
biventricular pacing improved the patient’s QOL,
NYHA class, motor ability (in 70% of cases), EF
(5–15%), etc., and reduced mortality (NNT: 9)
(Table 1); thus, biventricular pacing was conﬁrmed
to be a relatively safe method. These studies showed
that according to ACC/AHA/NASPE guidelines,20)
class III and class IV dilated cardiomyopathy or
ischemic cardiomyopathy with drug resistance and a
QRS duration of 130msec, a left ventricular end-
diastolic diameter of 55mm, and a left ventricular
ejection fraction of 35% constituted class IIa
indication for biventricular pacing. In Japan,21) class
III and class IV chronic heart failure with drug
resistance, QRS duration of 120msec and left
ventricular ejection fraction of 35% constitute
class I indication for biventricular pacing. For class
III and class IV patients with chronic heart failure
and drug resistance and a pacemaker implanted for
bradycardia, upgrading of the indication for biven-
tricular pacing (to IIa) has been approved.
Biventricular pacing has also been referred to as
CRT (cardiac resynchronization therapy), indicating
that synchrony in the cardiac septum and free wall is
restored by pacing. In actual clinical practice, left
ventricular synchrony is not necessarily restored by
only applying biventricular pacing and may require
3-point pacing or left ventricular pacing. Therefore,
in a practical sense, biventricular pacing could be
referred to as cardiac resynchronization therapy for
heart failure.
4. Problems in Application of Cardiac Re-
synchronization Therapy (CRT)
Pacing involves a mechanism to pace cardiac
tissues from the electrode placement site and does
not involve any other action. The indication for
pacing is determined by examining whether pacing
has beneﬁcial or harmful eﬀects on hemodynamics.
It should be clearly noted that in vivo a pacemaker is
a foreign body and that pacing itself cannot be
considered a physiological behavior. Because pacing
is used to treat serious heart failure conditions, there
are several problems associated with it, including
surgery-related death, troubles during implantation,
and various complications (Table 2). The problems
that are now drawing attention are as follows.
1) QRS complex duration in patients with indica-
tions for implantation
There are some patients with an indication for
implantation who have a narrow QRS complex and
no ventricular synchrony.22) Such patients may not
beneﬁt from CRT, even though beneﬁcial eﬀects of
CRT are expected under the current criteria. On the
contrary, there has been a report of patients with a
wide QRS complex with ventricular synchrony.
Under the conventional criteria used to decide the
indications for implantation, it has been conﬁrmed
that the percentage of patients for which CRT has
proved eﬀective is 70%, and that it was not eﬀective
in the remaining 30% (CRT-ineﬀective). As the
reasons for this, a wide QRS complex without left
ventricular dysynchrony or ineﬀective pacing due to
ventricular wall ﬁbrosis was proposed. To solve
these problems, use of tissue Doppler method,23)
ventricular synchrony evaluation by MRI, and
diagnostic imaging have been suggested.
2) Mild heart failure as an indication
Another issue is whether milder heart failure
(NYHA class II) is an indication for CRT. What
would be the results of CRT implemented at an
early stage? The survival rate is expected to
increase but this has not been proved so far. How
can CRT be eﬀective in patients with originally
mild heart failure?24) We cannot overlook whether
this indication makes sense economically, and the
long-term pacing complications. We are waiting for
the results of multicenter studies addressing these
issues, such as REVERSE (supervised by Medtronic
Co.) and MADIT-CRT (supervised by Boston
Scientiﬁc Co.).
3) Other issues concerning synchrony
The best way to measure cardiac function is by
looking at left ventricular contraction. When left
ventricular contraction is reduced, atrial contraction
and atrioventricular synchrony greatly aﬀect cardiac
output. If it were possible to control left and right
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ventricular synchrony, right atrio-ventricular syn-
chrony, left atrio-ventricular synchrony, and left and
right atrioventricular synchrony (i.e. synchrony at
four sites), the eﬀectiveness of CRT could be
further increased. However, the degree of eﬀective-
ness and how the phase should be set have not been
clariﬁed. These will probably diﬀer from patient to
patient.
Table 2 Incidence of complications in major large-scale studies.
Study CARE-HF
COMPANION
MIRACLE
CRTP CRTD
Number of cases (409) (617) (595) (569)
Unsuccessful lead placement 5% 13% 9% 7.6%
Perforation 3% 1.1% 0.8% 2%
Coronary dissection 2.6% 0.3% 0.5% 4%
Pneumothorax 1.5%
Surgery-related death 0.5% 0.8% 0.5% 0.4%
Lead displacement 6% 3.7%
Pacemaker infection 2.7% 1.3%
Surgery-related deaths were reported because patients with serious heart failure were involved in the
studies. The deaths that occurred within 30 days after surgery were not included. Although there
were many complications caused by implantation of the device, the mortality rate decreased. Future
technical improvement is expected to reduce complications.
Table 1 Summary of main multicenter studies conducted so far.
Study name
(Number of cases)
Year of publication
Study design Control patients condition Principal results
MUSTIC
(47)
2001
randomized
cross over
NYHA III, LVEF < 35% Improvement in 6-minute walk
PATH-CHF
(42)
2002
single blind
randomized
cross over controlled
NYHA III/IV, DCM
QRS > 120ms
Improvement in 6-minute walk
Improvement in maximum oxygen
consumption
MIRACLE
(453)
2002
prospective randomized
double blind
parallel controlled
NYHA III/IV, QRS  130ms
LVDd  55mm, EF  35%
6min walk < 450m
Improvement in 6-minute walk
Improvement in QOL
Improvement in NYHA class
MIRACLE-ICD
(369)
2003
prospective randomized
double blind multicenter
parallel controlled
NYHA III/IV, QRS  130ms
LVDd  55mm, EF  35%
Indicated for ICD
No improvement in 6-minute walk
Improvement in QOL
Improvement in NYHA class
CONTAK CD
(501)
2003
prospective randomized
cross over
parallel controlled
NYHA II/III/IV
QRS  120ms, EF  35%
Indicated for ICD
No signiﬁcant difference in overall
mortality and hospitalization rate
Improvements in EF and LVDd
were frequently seen in NYHA
class II cases.
COMPANION
(1292)
2004
prospective randomized
multicenter controlled
NYHA III/IV, QRS  120ms
EF  35%, PR  150ms
History of hospitalization
for heart failure of 12 months
CRT reduced the relative mortality
risk by 19% and CRTD by 20%.
CARE-HF
(409)
2005
prospective randomized
multicenter controlled
NYHA III/IV, QRS  120ms
EF < 35%, PEdelay > 140ms
Vvdelay > 40ms,
Ventricular wall dysynchrony
Improvement in overall mortality
Improvement in cardiac functions
Improvement in motor ability
Improvement in QOL
The CRT studies conducted in or before 2004 reported only on the improvement in cardiac function, QOL, and motor ability.
In 2005, the CARE-HF study revealed that CRT improved the prognosis of patients with heart failure. The reason for this
might be the use of more exact indicators of ventricular asynchrony in the CARE-HF study than in other studies.
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4) Possibility of causing severe ventricular ar-
rhythmia complications
The multicenter studies conducted so far have
occasionally reported on individual patients in
whom CRT induced severe ventricular arrhythmia,25)
although the relationship has not been clariﬁed by a
statistical study.26) However, it is clear that the heart
failure itself is a risk factor of sudden death,27) and
deﬁbrillation must be considered when CRT is
conducted. The COMPANION study has shown
higher eﬀectiveness of CRT-D (CRT-deﬁbrillation)
than CRT-P (CRT-pacing) based on the survival
rate.28)
5) Application of CRT to AF
While atrioventricular resynchronization is not
expected to have an eﬀect on atrial ﬁbrillation (AF),
the eﬀectiveness of CRT has been expected because
synchrony in the ventricular wall, slowed heart rate,
and stabilized heart rate can be obtained. The PAVE
study found that the use of CRT in ablate and pace
therapy for heart failure due to atrial ﬁbrillation with
a rapid ventricular response showed improvement
of cardiac function in patients with heart failure
compared with the conventional pacing method.
Selection of the patients with atrial ﬁbrillation for
whom CRT is indicated is an issue for future
discussion.
In addition, treatment methods other than CRT
should also be taken into account, considering the
ease and success rate of maintaining or controlling
sinus rhythm in atrial ﬁbrillation by catheter abla-
tion.
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